Beiersdorf, Rubedo Team Up to Target Senescence

The collaborators will explore novel compounds derived from Rubedo's topical dermatology program that have senolytic and anti-inflammatory properties.
The collaborators will explore novel compounds derived from Rubedo's topical dermatology program that have senolytic and anti-inflammatory properties.
Image by oneinchpunch at Adobe Stock

Beiersdorf and Rubedo Life Science announced a partnership to develop a breakthrough anti-aging solution for facial care by targeting senescence. Per the companies, the collaboration will leverage Rubedo's cutting-edge research in the field of cellular senescence and Beiersdorf's market presence to develop groundbreaking anti-aging products.

See related: Beiersdorf Pairs Glycation Inhibitor with CoQ10 in its Latest Nivea Q10 Launch

More specifically, the collaborators will explore novel compounds derived from Rubedo's topical dermatology program that have senolytic and anti-inflammatory properties.

"Our mission is to define the future of skin care through breakthrough innovation," commented Beiersdorf CEO Vincent Warnery. "By partnering with Rubedo and combining cutting-edge expertise from both sides, we aim to redefine the standards in anti-age skin care.”

Beiersdorf additionally joins Rubedo as investor, having participated in its recently closed Series A financing round through its Oscar & Paul Corporate Venture Capital Fund.

More in Companies